Solutia Reports Third Quarter 20...(23 Loss from Discontinued Operations ...)

Date:10/26/2009

23 Loss from Discontinued Operations, net of tax -- (28) --- ---- Net Income (Loss) 31 (5) Net Income attributable to noncontrolling interest 2 2 --- --- Net Income (Loss) attributable to Solutia $29 $(7) === ==== Basic and Diluted Income (Loss) per Share: Income from Continuing Operations attributable to Solutia $0.24 $0.28 Loss from Discontinued Operations -- (0.37) --- ------ Net Income (Loss) attributable to Solutia $0.24 $(0.09) ===== ======= Successor Successor Predecessor --------- --------- ----------- Nine Seven Two Months Months Months Ended Ended Ended September 30, September 30, February 29, 2009 2008 2008 ---- ---- ---- Net Sales $1,197 $1,346 $335 Cost of goods sold 858 1,063 241 --- ----- --- Gross Profit 339
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009